|Bee Group, CH
|BEE Group AG is home to leading companies in the emerging field of advanced uses of the electroencephalogram (EEG) for medical applications, in particular: 1) Diagnostics: This is mainly about discovery, validation and approval of EEG/ERP-based biomarkers (neuromarkers) as well as tools and services that utilize the markers to enhance the precision of diagnoses of mental health disorders and to help to improve personalized therapy. 2) Therapy: BEE Group invests in the development of clinical devices and software for neurofeedback (EEG-biofeedback) that support evidence-based neurofeedback techniques. Bee is leading in EEG signal processing, advanced feature extraction and complex feedback animation control. BEE Group maintains a network of cooperation partners in science and clinical application, one of which is the University of Zurich, where BEE currently supports studies regarding advanced neurofeedback approaches for treatment of Tinnitus.
|Brain Products, DE
|Established in 1997, Brain Products GmbH has rapidly grown to become one of the leading suppliers of electroencephalography (EEG) systems for neurophysiological recording. Brain Products supplements a comprehensive product suite with a worldwide network of knowledge brought to life by our distributors and business partners, collaborative projects with universities, in-house Research and Development, the collaboration of Brain Products’ experienced team, industry experts, and clients resulting in continued product innovation.
|Carl van Himbeeck
|Cochlear’s mission statement says: We help people hear and be heard. Cochlear is global market leader in implantable hearing solutions. 7 out of 10 patients choose for Cochlear. The Cochlear Technology Center in Belgium is one of the companies’ main research facilities.
|Del Bo Technologia, IT
|Luca del Bo
|Del Bo tecnologia per l'ascolto - Tinnitus Clinic is a private company focusing on the development and fitting of instruments for auditory and electrical stimulation. The treatment of chronic tinnitus is a main topic of our clinical activity since the 1999. We are happy to be part of the ESIT Project and we are ready to welcome students and researchers in our Clinic in Milano.
|Medien LB, DE
|MedienLB is currently the market leader for educational films in Germany. Thus, MLB is in contact with over 40,000 schools, 678,100 teachers and 9,727,000 pupils in Germany and German speaking countries. The educational films are shown in South Africa, Sweden, USA, France and many other countries. MedienLB educational films are highly recognised: Erasmus Euro Media Award 2011 and 2013, Winner of the Medal of Excellence 2014, Laureate of the Comenius-EduMedia-Award 2014 for outstanding educational, content and creative ICT-based education materials in the field of teaching and teaching management systems. Another 6 Comenius awards in 2015!
|Pinpoint Scotland, UK
|ENT and Audiology News is an award-winning, bimonthly specialty magazine for Ear, Nose and Throat and Audiology professionals with an international circulation of around 16,000. The magazine is now in its 25th year of publication and continues to lead the field – distributed to readers in more than 140 countries worldwide.
Sensorion is a specialty pharmaceutical company dedicated to the development of targeted and innovative treatments for inner ear disease such as hearing loss, tinnitus and vestibular dysfunction. Originated as a spin-off in 2009 from the INSERM in Montpellier (France), the company has since evolved into a publicly traded (Alternext Paris: ALSEN), clinical stage pharmaceutical company with 19 full-time employees of which 15 are occupied full-time in preclinical and clinical R&D. With a management team constituted of experienced pharma executives and scientists, Sensorion’s headquarters with an internal in vitro and in vivo screening platform are located on the AAALAC accredited Montpellier R&D site of Sanofi, providing access to first-class infrastructure and facilities. The company has 2 active clinical programs, ongoing collaborations with academic institutions worldwide and has received both national level and European R&D grants. Jonas Dyhrfjeld-Jonsen comments on ESIT: "Tinnitus is a severely debilitating condition which currently constitutes a significant unmet medical need with no satisfactory solutions for a growing patient population worldwide. Sensorion is pleased to be part of the European School on Interdisciplinary Tinnitus Research initiative, which we expect will contribute to moving forward the understanding of the etiology and pathophysiology of tinnitus, thus facilitating the development of safe and effective treatments for patients."
|Sivantos is one of the world’s top manufacturers of hearing aids. In fact, we are proud to develop and manufacture one out of every four hearing aids being used worldwide. We have helped people with hearing loss for more than 100 years. Today, Sivantos Group employs about 5,000 people in more than 25 countries. Sivantos offers hearing aids branded Signia, Siemens, Audio Service, Rexton and A&M. Complementary accessories, fitting software, smartphone apps and diagnostics workflow solutions are also part of its portfolio. Tinnitus usually goes hand in hand with hearing loss. This is why, for many years, Sivantos has developed and integrated specific therapies. Relief for tinnitus patients through hearing aids is widely considered one of Sivantos’ strengths. People with tinnitus would like to have immediate relief. Study results show that with our latest development, Notch Therapy, tinnitus shows signs of improvement after only 3 weeks (Powers et al. 2016). In comparison, the well-known Tinnitus Retraining Therapy (TRT) shows an improvement after about six to 12 months. So no wonder, Sivantos is well positioned to sponsor ESIT. „ESIT will take the science of understanding tinnitus and developing effective solutions for its treatment to a new level. Sivantos is looking forward to playing a supporting role in this international research project to improve the quality of life of people living with tinnitus”, says Ronny Hannemann, Audiology engineer at Sivantos.
|Sonormed is a Hamburg-based medical technology company with a strong focus on digital audiology. An interdisciplinary team of sound engineers, computer scientists and neurobiologists develops state-of-the art solutions to improve hearing impairments. Building a unique infrastructure that integrates regulatory requirements (e.g. medical device regulation), specific needs of ENT physicians and the requirements for reimbursement is the core mission of Sonormed. Based on this infrastructure Sonormed builds a portfolio of related products for diagnostics, therapeutic use and workflow management. Sonormed’s most widely recognised solution is Tinnitracks, a fully digital therapeutic app for tinnitus patients. Tinnitracks is a certified medical solution providing access to the scientifically validated Tailor-Made Notched Training (TMNMT), a neuro-acoustic treatment approach that targets hyperactive nerve cells underlying the perception of tinnitus. In Germany, Tinnitracks has become the first therapeutic app to be reimbursed by statutory and private health insurances. Heading towards a complete integration into the existing healthcare system, Sonormed was able to receive numerous prestigious awards for the development of Tinnitracks, e.g.,the renowned US-technology-award SXSW in “Digital Health & Life Science”.
|Soterix Medical Inc. (SMI) was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation. SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 200 medical centers in the US and worldwide. From the most targeted non-invasive clinical systems to the most portable units, Soterix Medical provides clinicians and patients with unique and adaptable solutions. SMI has developed an exclusive technology called High-Definition tDCS. This is the only clinical validated system for non-invasive application of therapeutic current to desired brain regions. There is no similar device produced in Europe.